Anthera Pharmaceuticals (ANTH) 2.73 $ANTH
Anthera Pharmaceuticals Announces Personnel Changes
PR Newswire - Mon Mar 31, 3:30PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Steven Engle to and the departure of Dr. James Healy, MD, PhD from its Board of Directors.
Anthera Pharmaceuticals Reports 2013 Fourth Quarter And Fiscal Year Financial Results and Operational Update
PR Newswire - Wed Mar 12, 5:01PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the fourth quarter and year ended December 31, 2013.
Global Systemic Lupus Erythematosus and Lupus Nephritis Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/3dtg7v/pharmapoint) has announced the addition of the "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022" report to their offering. Sales for SLE and LN by Region, 2012-2022 2012 Systemic Lupus Erythematosus (SLE) drug sales to be over $473.6m across the seven major markets covered in this report: US, France, Germany, Italy, Spain, UK and Japan. By the end of the forecast period in 2022, sales will grow to over $1.1 billion with a CAGR of 9.36%. Focusing on Lupus Nephritis (LN), The authors estimates 2012 drug sales to be over $216.6m across the seven major markets covered in this report. By the end of the forecast period in 2022, sales will grow to over $505.9m with a CAGR of 8.86%. The growth in the SLE and LN therapeutics will be driven by: - Increasing uptake of biologics, including GlaxoSmithKline's Benlysta (belimumab), the only approved biologic for SLE, and off-label use of Roche's Rituxan - The launch of Benlysta in Japan in 2016 - The launch of new biologic drugs during the second half of the forecast period - The increasing number of prevalent cases of SLE and LN The uptake of new biologic drugs that will enter the SLE and LN markets will be initially low. Biologic drugs will primarily target lupus patients with high disease activity (approximately 10%-15% of all SLE patients) and therefore, currently marketed biologic dugs and new entrants will compete for a small segment of the total SLE patient population. This view is based on the available clinical trial data to date for Benlysta, the clinical trial design for current pipeline products and The authors's primary research (conducted in July-August 2013). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook Companies Mentioned - GlaxoSmithKline - Roche - UCB - Eli Lilly and Company - Bristol-Myers Squibb - Anthera Pharmaceuticals - ImmuPharma - Merck Serono For more information visit http://www.researchandmarkets.com/research/3d...harmapoint
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/lt4bvv/lupus_nephritis) has announced the addition of the "Lupus Nephritis Global Clinical Trials Review, H1, 2014" report to their offering. Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Lupus Nephritis Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials Latest Clinical Trials News on Lupus Nephritis Clinical Trial Profiles Clinical Trial Overview of Top Companies Clinical Trial Overview of Novartis AG Clinical Trial Overview of Astellas Pharma Inc. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Clinical Trial Overview of Biogen Idec Inc. Clinical Trial Overview of Anthera Pharmaceuticals Inc. Clinical Trial Overview of Teva Pharmaceutical Industries Limited Clinical Trial Overview of La Jolla Pharmaceutical Company Clinical Trial Overview of E. Merck KG Clinical Trial Overview of Bristol-Myers Squibb Company Clinical Trial Overview of Aurinia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government Clinical Trial Overview of Nanjing University Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Trial Overview of Sun Yat-sen University Clinical Trial Overview of Faculty of Pharmaceutical Sciences, Chulalongkorn University Clinical Trial Overview of Chinese University of Hong Kong Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of All India Institute of Medical Sciences Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases Clinical Trial Overview of Zhejiang University Clinical Trial Overview of The Rogosin Institute Five Key Clinical Profiles Appendix For more information visit http://www.researchandmarkets.com/research/lt..._nephritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nephropathy - Pipeline Review, H2 2013 Report Available Now
M2 - Fri Feb 14, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/d4j7jb/nephropathy) has announced the addition of the "Nephropathy - Pipeline Review, H2 2013" report to their offering. 'Nephropathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Nephropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nephropathy. Scope - A snapshot of the global therapeutic scenario for Nephropathy. - A review of the Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Nephropathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Nephropathy Overview Therapeutics Development Pipeline Products for Nephropathy - Overview Pipeline Products for Nephropathy - Comparative Analysis Nephropathy - Therapeutics under Development by Companies Nephropathy - Therapeutics under Investigation by Universities/Institutes Nephropathy - Pipeline Products Glance Nephropathy - Products under Development by Companies Nephropathy - Products under Investigation by Universities/Institutes Nephropathy - Companies Involved in Therapeutics Development Nephropathy - Therapeutics Assessment Drug Profiles rituximab - Drug Profile blisibimod - Drug Profile BMS-813160 - Drug Profile IgA Proteases For Nephropathy - Drug Profile R&D Progress PRM-151 - Drug Profile TRPC4/C5 Antagonist - Drug Profile IkT-001 Pro - Drug Profile IKT-014 - Drug Profile MS-417 - Drug Profile R&D Progress Featured News & Press Releases Companies Mentioned Bristol-Myers Squibb Company Promedior, Inc. Hydra Biosciences, Inc. Anthera Pharmaceuticals Inc. IGAN Biosciences Inhibikase Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/d4...ephropathy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Thirty-Eight Percent of Workers Have Dated a Co-Worker, Finds CareerBuilder Survey
PR Newswire - Thu Feb 13, 5:00AM CST
Looking for a Valentine? The office may be a good place to start. CareerBuilder's annual survey on office romance found nearly two in five (38 percent) U.S. workers have dated someone who worked for the same company, and 16 percent said they have done so more than once.
Anthera Pharmaceuticals to Present at Leerink Swann, Cowen & Co., and BIO CEO Healthcare Conferences
PR Newswire - Thu Jan 30, 3:42PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update on the progress of the Company's development programs including additional plans for blisibimod beyond autoimmune disorders at three conferences in February and early March.
PSM Holdings, Inc. (PSMH) Announces Additions to its Approved States List
PR Newswire - Thu Jan 30, 8:00AM CST
PSM Holdings, Inc. (OTCBB: PSMH), announces the expansion of PrimeSource Mortgage, Inc. into the states of Arizona and Virginia.
FLG Partners Announces Chris Lowe as a New Partner
Marketwire - Tue Jan 28, 12:09PM CST
FLG Partners, LLC (www.flgpartners.com), announced today the addition of a new partner to the consulting and services firm, bringing the number of partners to 23.
Flowserve Announces New Mobile Device App for Gestra Products
Thomson Reuters ONE - Thu Jan 09, 6:06PM CST
Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022
M2 - Wed Dec 11, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/n54922/blisibimod) has announced the addition of the "Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022" report to their offering. Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE. Anthera Pharmaceuticals is developing blisibimod as a potential treatment for autoimmune diseases, including SLE. Amgen initiated the development of blisibimod, but in January 2008 Anthera Pharmaceuticals entered into a license agreement with Amgen for the exclusive and worldwide rights to develop and commercialize this product. Scope - Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Blisibimod including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Blisibimod for the top seven countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Blisibimod 9 Appendix For more information visit http://www.researchandmarkets.com/research/n54922/blisibimod
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 27, 4:00PM CST
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, and May Liu, Senior Vice President of Finance and Administration, will present a corporate update at the 2013 Annual Piper Jaffray Healthcare Conference.
Two Drugs, Designed To Help Patients, Actually Hurt Them
at The Street - Tue Nov 19, 9:38AM CST
A heart drug from Anthera and a skin cancer vaccine from Vical caused patients harm, according to results from clinical trials presented Monday.
Biogen Upped to Outperform - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 19, 9:30AM CDT
Strong performance in the first half of 2013, raised outlook and improving prospects work in the company's favor.
Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013 Out Now
M2 - Thu Sep 12, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87csvr/cardiovascular) has announced the addition of the "Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013" provides data on the Cardiovascular Inflammation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cardiovascular Inflammation. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cardiovascular Inflammation. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Anthera Pharmaceuticals Inc. AstraZeneca PLC Cumberland Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. Genentech, Inc. GlaxoSmithKline plc Immunomedics, Inc. Innovaderm Research Inc. Janssen Biotech, Inc. Novartis AG Pluristem Therapeutics Inc. RNL BIO Co., Ltd. Robert Bosch GmbH Sanofi TNO Pharma Teijin Pharma Limited Troikaa Pharmaceuticals Ltd. UMC Utrecht Holding BV For more information visit http://www.researchandmarkets.com/research/87...iovascular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Signal Daily Stock Watch - Anthera Pharmaceuticals, Inc., (NASDAQ: ANTH)
WorldStockWire - Wed Sep 04, 2:00AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Data Published on Alnylam's ATTR Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 29, 3:00PM CDT
Alnylam announced that results from phase I studies on ALN-TTR01 and ALN-TTR02 have been published in the NEJM.
Alnylam Wins Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 21, 1:20PM CDT
Alnylam announced that the FDA granted orphan drug designation to ALN-AT3 for the hemophilia A indication.
Voluntary Recall at Alexion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 21, 9:30AM CDT
Alexion voluntarily recalled a solitary Soliris vial.
Good News for Alnylam - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 19, 5:10PM CDT
The FDA granted Orphan Drug Designation to Alnylam's ALN-AT3 for the treatment of hemophilia B.
Anthera Pharmaceuticals Announces Personnel Changes
PR Newswire - Mon Mar 31, 3:30PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Steven Engle to and the departure of Dr. James Healy, MD, PhD from its Board of Directors.
Anthera Pharmaceuticals Reports 2013 Fourth Quarter And Fiscal Year Financial Results and Operational Update
PR Newswire - Wed Mar 12, 5:01PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the fourth quarter and year ended December 31, 2013.
Global Systemic Lupus Erythematosus and Lupus Nephritis Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/3dtg7v/pharmapoint) has announced the addition of the "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022" report to their offering. Sales for SLE and LN by Region, 2012-2022 2012 Systemic Lupus Erythematosus (SLE) drug sales to be over $473.6m across the seven major markets covered in this report: US, France, Germany, Italy, Spain, UK and Japan. By the end of the forecast period in 2022, sales will grow to over $1.1 billion with a CAGR of 9.36%. Focusing on Lupus Nephritis (LN), The authors estimates 2012 drug sales to be over $216.6m across the seven major markets covered in this report. By the end of the forecast period in 2022, sales will grow to over $505.9m with a CAGR of 8.86%. The growth in the SLE and LN therapeutics will be driven by: - Increasing uptake of biologics, including GlaxoSmithKline's Benlysta (belimumab), the only approved biologic for SLE, and off-label use of Roche's Rituxan - The launch of Benlysta in Japan in 2016 - The launch of new biologic drugs during the second half of the forecast period - The increasing number of prevalent cases of SLE and LN The uptake of new biologic drugs that will enter the SLE and LN markets will be initially low. Biologic drugs will primarily target lupus patients with high disease activity (approximately 10%-15% of all SLE patients) and therefore, currently marketed biologic dugs and new entrants will compete for a small segment of the total SLE patient population. This view is based on the available clinical trial data to date for Benlysta, the clinical trial design for current pipeline products and The authors's primary research (conducted in July-August 2013). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook Companies Mentioned - GlaxoSmithKline - Roche - UCB - Eli Lilly and Company - Bristol-Myers Squibb - Anthera Pharmaceuticals - ImmuPharma - Merck Serono For more information visit http://www.researchandmarkets.com/research/3d...harmapoint
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/lt4bvv/lupus_nephritis) has announced the addition of the "Lupus Nephritis Global Clinical Trials Review, H1, 2014" report to their offering. Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Lupus Nephritis Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials Latest Clinical Trials News on Lupus Nephritis Clinical Trial Profiles Clinical Trial Overview of Top Companies Clinical Trial Overview of Novartis AG Clinical Trial Overview of Astellas Pharma Inc. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Clinical Trial Overview of Biogen Idec Inc. Clinical Trial Overview of Anthera Pharmaceuticals Inc. Clinical Trial Overview of Teva Pharmaceutical Industries Limited Clinical Trial Overview of La Jolla Pharmaceutical Company Clinical Trial Overview of E. Merck KG Clinical Trial Overview of Bristol-Myers Squibb Company Clinical Trial Overview of Aurinia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government Clinical Trial Overview of Nanjing University Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Trial Overview of Sun Yat-sen University Clinical Trial Overview of Faculty of Pharmaceutical Sciences, Chulalongkorn University Clinical Trial Overview of Chinese University of Hong Kong Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of All India Institute of Medical Sciences Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases Clinical Trial Overview of Zhejiang University Clinical Trial Overview of The Rogosin Institute Five Key Clinical Profiles Appendix For more information visit http://www.researchandmarkets.com/research/lt..._nephritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nephropathy - Pipeline Review, H2 2013 Report Available Now
M2 - Fri Feb 14, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/d4j7jb/nephropathy) has announced the addition of the "Nephropathy - Pipeline Review, H2 2013" report to their offering. 'Nephropathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Nephropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nephropathy. Scope - A snapshot of the global therapeutic scenario for Nephropathy. - A review of the Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Nephropathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Nephropathy Overview Therapeutics Development Pipeline Products for Nephropathy - Overview Pipeline Products for Nephropathy - Comparative Analysis Nephropathy - Therapeutics under Development by Companies Nephropathy - Therapeutics under Investigation by Universities/Institutes Nephropathy - Pipeline Products Glance Nephropathy - Products under Development by Companies Nephropathy - Products under Investigation by Universities/Institutes Nephropathy - Companies Involved in Therapeutics Development Nephropathy - Therapeutics Assessment Drug Profiles rituximab - Drug Profile blisibimod - Drug Profile BMS-813160 - Drug Profile IgA Proteases For Nephropathy - Drug Profile R&D Progress PRM-151 - Drug Profile TRPC4/C5 Antagonist - Drug Profile IkT-001 Pro - Drug Profile IKT-014 - Drug Profile MS-417 - Drug Profile R&D Progress Featured News & Press Releases Companies Mentioned Bristol-Myers Squibb Company Promedior, Inc. Hydra Biosciences, Inc. Anthera Pharmaceuticals Inc. IGAN Biosciences Inhibikase Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/d4...ephropathy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Thirty-Eight Percent of Workers Have Dated a Co-Worker, Finds CareerBuilder Survey
PR Newswire - Thu Feb 13, 5:00AM CST
Looking for a Valentine? The office may be a good place to start. CareerBuilder's annual survey on office romance found nearly two in five (38 percent) U.S. workers have dated someone who worked for the same company, and 16 percent said they have done so more than once.
Anthera Pharmaceuticals to Present at Leerink Swann, Cowen & Co., and BIO CEO Healthcare Conferences
PR Newswire - Thu Jan 30, 3:42PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update on the progress of the Company's development programs including additional plans for blisibimod beyond autoimmune disorders at three conferences in February and early March.
PSM Holdings, Inc. (PSMH) Announces Additions to its Approved States List
PR Newswire - Thu Jan 30, 8:00AM CST
PSM Holdings, Inc. (OTCBB: PSMH), announces the expansion of PrimeSource Mortgage, Inc. into the states of Arizona and Virginia.
FLG Partners Announces Chris Lowe as a New Partner
Marketwire - Tue Jan 28, 12:09PM CST
FLG Partners, LLC (www.flgpartners.com), announced today the addition of a new partner to the consulting and services firm, bringing the number of partners to 23.
Flowserve Announces New Mobile Device App for Gestra Products
Thomson Reuters ONE - Thu Jan 09, 6:06PM CST
Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022
M2 - Wed Dec 11, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/n54922/blisibimod) has announced the addition of the "Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022" report to their offering. Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE. Anthera Pharmaceuticals is developing blisibimod as a potential treatment for autoimmune diseases, including SLE. Amgen initiated the development of blisibimod, but in January 2008 Anthera Pharmaceuticals entered into a license agreement with Amgen for the exclusive and worldwide rights to develop and commercialize this product. Scope - Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Blisibimod including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Blisibimod for the top seven countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Blisibimod 9 Appendix For more information visit http://www.researchandmarkets.com/research/n54922/blisibimod
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 27, 4:00PM CST
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, and May Liu, Senior Vice President of Finance and Administration, will present a corporate update at the 2013 Annual Piper Jaffray Healthcare Conference.
Two Drugs, Designed To Help Patients, Actually Hurt Them
at The Street - Tue Nov 19, 9:38AM CST
A heart drug from Anthera and a skin cancer vaccine from Vical caused patients harm, according to results from clinical trials presented Monday.
Biogen Upped to Outperform - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 19, 9:30AM CDT
Strong performance in the first half of 2013, raised outlook and improving prospects work in the company's favor.
Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013 Out Now
M2 - Thu Sep 12, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87csvr/cardiovascular) has announced the addition of the "Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013" provides data on the Cardiovascular Inflammation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cardiovascular Inflammation. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cardiovascular Inflammation. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Anthera Pharmaceuticals Inc. AstraZeneca PLC Cumberland Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. Genentech, Inc. GlaxoSmithKline plc Immunomedics, Inc. Innovaderm Research Inc. Janssen Biotech, Inc. Novartis AG Pluristem Therapeutics Inc. RNL BIO Co., Ltd. Robert Bosch GmbH Sanofi TNO Pharma Teijin Pharma Limited Troikaa Pharmaceuticals Ltd. UMC Utrecht Holding BV For more information visit http://www.researchandmarkets.com/research/87...iovascular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Signal Daily Stock Watch - Anthera Pharmaceuticals, Inc., (NASDAQ: ANTH)
WorldStockWire - Wed Sep 04, 2:00AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Data Published on Alnylam's ATTR Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 29, 3:00PM CDT
Alnylam announced that results from phase I studies on ALN-TTR01 and ALN-TTR02 have been published in the NEJM.
Alnylam Wins Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 21, 1:20PM CDT
Alnylam announced that the FDA granted orphan drug designation to ALN-AT3 for the hemophilia A indication.
Voluntary Recall at Alexion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 21, 9:30AM CDT
Alexion voluntarily recalled a solitary Soliris vial.
Good News for Alnylam - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 19, 5:10PM CDT
The FDA granted Orphan Drug Designation to Alnylam's ALN-AT3 for the treatment of hemophilia B.
